Neuro-Oncology
Reviews


Volume 22 Number 5
May 2020


Home > Publications > Neuro-Oncology Reviews > Volume 22, Year 2020 > Number 5, May



CONTENTS


CENTRAL NERVOUS SYSTEM TUMORS




GLIOMAS


HIGH-GRADE GLIOMAS


LOW-GRADE GLIOMAS




DIFFUSE ASTROCYTIC AND OLIGODENDROGLIAL TUMORS


GLIOBLASTOMA


DIFFUSE MIDLINE GLIOMA




EMBRYONAL TUMORS


MEDULLOBLASTOMA




LYMPHOMAS




FAMILIAL TUMOR SYNDROMES





CENTRAL NERVOUS SYSTEM TUMORS


Baliga S, Gandola L, Timmermann B, Gail H, Padovani L, Janssens GO, Yock TI.
Brain tumors: Medulloblastoma, ATRT, ependymoma.
Pediatr Blood Cancer. [2020 May 9]. 2020;e28395. Doi 10.1002/pbc.28395. _




Bhattacharya D, Pomeroy SL, Pomeranz Krummel DA, Sengupta S.
Epigenetics and survivorship in pediatric brain tumor patients.
J Neurooncol. [2020 May 25]. 2020;10.1007/s11060-020-03535-3. Doi 10.1007/s11060-020-03535-3. _




Blue R, Miranda SP, Gu BJ, Chen HI.
A Primer on Human Brain Organoids for the Neurosurgeon.
Neurosurgery. [2020 May 18]. 2020;nyaa171. Doi 10.1093/neuros/nyaa171. _




Brown JM.
Radiation Damage to Tumor Vasculature Initiates a Program that Promotes Tumor Recurrences.
Int J Radiat Oncol Biol Phys. [2020 May 27]. 2020;S0360-3016(20)31185-8. Doi 10.1016/j.ijrobp.2020.05.028. _




Cacciotti C, Fleming A, Ramaswamy V.
Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy.
J Pathol. [2020 May 11]. 2020;10.1002/path.5457. Doi 10.1002/path.5457. _




Daggubati LC, Eichberg DG, Ivan ME, Hanft S, Mansouri A, Komotar RJ, D'Amico RS, Zacharia BE.
Telemedicine for Outpatient Neurosurgical Oncology Care: Lessons Learned for the Future During the COVID-19 Pandemic.
World Neurosurg. [2020 May 22]. 2020:S1878-8750(20)31111-6. Doi 10.1016/j.wneu.2020.05.140. _




Deora H, Tripathi M, Tewari MK, Ahuja CK, Kumar N, Kaur A, Kamboj P.
Role of gamma knife radiosurgery in the management of intracranial gliomas.
Neurol India. [2020 May 15]. 2020;68(2):290-298. Doi 10.4103/0028-3886.284356. _




Feldman AZ, Jennings LJ, Wadhwani NR, Brat DJ, Horbinski CM.
The Essentials of Molecular Testing in CNS Tumors: What to Order and How to Integrate Results.
Curr Neurol Neurosci Rep. 2020 May 22. 2020;20(7):23. Doi 10.1007/s11910-020-01041-7. _




Ferraris C, Cavalli R, Panciani PP, Battaglia L.
Overcoming the Blood-Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours.
Int J Nanomedicine. 2020 Apr 30. 2020;15:2999-3022. Doi 10.2147/IJN.S231479. _




Garbayo E, Pascual-Gil S, Rodríguez-Nogales C, Saludas L, Estella-Hermoso de Mendoza A, Blanco-Prieto MJ.
Nanomedicine and drug delivery systems in cancer and regenerative medicine.
WIREs Nanomed Nanobiotechnol. 2020 Apr 29. 2020;e1637. Doi 10.1002/wnan.1637. _




Huang AZ, Delaidelli A, Sorensen PH.
RNA modifications in brain tumorigenesis.
Acta Neuropathol Commun. 2020 May 6. 2020;8(1):64. Doi 10.1186/s40478-020-00941-6. _




Kim SK, Moon J, Cho JM, Kim KH, Kim SH, Kim YI, Kim YZ, Kim HS, Dho YS, Park JS, Park JE, Seo Y, Sung KS, Song JH, Wee CW, Yoon WS, Yoon HI, Lee SH, Lim DH, Im JH, Chang JH, Han MH, Hong JB, Hwang K, Park CK, Lee YS, Gwak HS; KSNO Guideline Working Group.
A National Consensus Survey for Current Practice in Brain Tumor Management I: Antiepileptic Drug and Steroid Usage.
Brain Tumor Res Treat. 2020 Apr 30. 2020;8(1):1-10. Doi 10.14791/btrt.2020.8.e5. _




Kim SK, Yoon HI, Yoon WS, Cho JM, Moon J, Kim KH, Kim SH, Kim YI, Kim YZ, Kim HS, Dho YS, Park JS, Park JE, Seo Y, Sung KS, Song JH, Wee CW, Lee SH, Lim DH, Im JH, Chang JH, Han MH, Hong JB, Hwang K, Park CK, Lee YS, Gwak HS; KSNO Guideline Working Group.
A National Consensus Survey for Current Practice in Brain Tumor Management II: Diffuse Midline Glioma and Meningioma.
Brain Tumor Res Treat. 2020 Apr 30. 2020;8(1):11-19. Doi 10.14791/btrt.2020.8.e6. _




Kim SK, Park JE, Kim KH, Cho JM, Moon J, Yoon WS, Kim SH, Kim YI, Kim YZ, Kim HS, Dho YS, Park JS, Yoon HI, Seo Y, Sung KS, Song JH, Wee CW, Lee SH, Lim DH, Im JH, Chang JH, Han MH, Hong JB, Hwang K, Park CK, Lee YS, Gwak HS; KSNO Guideline Working Group.
A National Consensus Survey for Current Practice in Brain Tumor Management III: Brain Metastasis and Primary Central Nervous System Lymphoma.
Brain Tumor Res Treat. 2020 Apr;8(1):20-28. Doi 10.14791/btrt.2020.8.e7. _




Kocher M, Ruge MI, Galldiks N, Lohmann P.
Applications of radiomics and machine learning for radiotherapy of malignant brain tumors.
Strahlenther Onkol. [2020 May 11]. 2020;10.1007/s00066-020-01626-8. Doi 10.1007/s00066-020-01626-8. _




Muggia FM et al, PDQ Adult Treatment Editorial Board.
Adult Central Nervous System Tumors Treatment (PDQ®): Patient Version.
PDQ Cancer Inf Summ. 2020 May 7. Natl Cancer Inst. NBK66023. _




Munier S, Ginalis EE, Patel NV, Danish S, Hanft S.
Radiation Necrosis in Intracranial Lesions.
Cureus. 2020 Apr 9. 2020;12(4):e7603. Doi 10.7759/cureus.7603. _




Ritchey AK et al., PDQ Pediatric Treatment Editorial Board.
Childhood Brain and Spinal Cord Tumors Treatment Overview (PDQ®): Patient Version.
PDQ Cancer Inf Summ. 2020 May 7. Natl Cancer Inst. NBK65913. _




Schiavolin S, Raggi A, Scaratti C, Toppo C, Silvaggi F, Sattin D, Broggi M, Ferroli P, Leonardi M.
Outcome prediction in brain tumor surgery: a literature review on the influence of nonmedical factors.
Neurosurg Rev. [2020 May 7]. Doi 10.1007/s10143-020-01289-0. _




Soleman J, Kozyrev DA, Ben-Sira L, Constantini S, Roth J.
Management of incidental brain tumors in children: a systematic review.
Childs Nerv Syst. [2020 May 6]. 2020;10.1007/s00381-020-04658-8. Doi 10.1007/s00381-020-04658-8. _




Xiao F, Lv S, Zong Z, Wu L, Tang X, Kuang W, Zhang P, Li X, Fu J, Xiao M, Wu M, Wu L, Zhu X, Huang K, Guo H.
Cerebrospinal fluid biomarkers for brain tumor detection: clinical roles and current progress.
Am J Transl Res. [2020 Apr 15]. 2020;12(4):1379-1396. Issn1943-8141/AJTR0106905. _



GLIOMAS


Abdalla G, Dixon L, Sanverdi E, Machado PM, Kwong JSW, Panovska-Griffiths J, Rojas-Garcia A, Yoneoka D, Veraart J, Van Cauter S, Abdel-Khalek AM, Settein M, Yousry T, Bisdas S.
The diagnostic role of diffusional kurtosis imaging in glioma grading and differentiation of gliomas from other intra-axial brain tumours: a systematic review with critical appraisal and meta-analysis.

Neuroradiology. [2020 May 4]. 2020;10.1007/s00234-020-02425-9. Doi 10.1007/s00234-020-02425-9. _




Armstrong TS, Dirven L, Arons D, Bates A, Chang SM, Coens C, Espinasse C, Gilbert MR, Jenkinson D, Kluetz P, Mendoza T, Rubinstein L, Sul J, Weller M, Wen PY, van den Bent MJ, Taphoorn MJB.
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report.
Lancet Oncol. 2020 Feb 1. 2020;21(2):e97-e103. Doi 10.1016/S1470-2045(19)30796-X. _




Armstrong TS, Chang SM, Jenkinson D, Kluetz P, Taphoorn MJB.
Glioma patient-reported outcome assessment in clinical care - Authors' reply.
Lancet Oncol. 2020 May 1. 2020;21(5):e231. Doi 10.1016/S1470-2045(20)30241-2. _
Referring to: Tuleasca C, et al.,Glioma patient-reported outcome assessment in clinical care. Lancet Oncol. 2020 May 1. 2020;21(5):e230. Doi 10.1016/S1470-2045(20)30141-8. _
In turn Referring to: Armstrong TS, et al.,
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. Lancet Oncol. 2020 Feb 1. 2020;21(2):e97-e103. Doi 10.1016/S1470-2045(19)30796-X. _




Garcia-Fabiani MB, Ventosa M, Comba A, Candolfi M, Nicola Candia AJ, Alghamri MS, Kadiyala P, Carney S, Faisal SM, Schwendeman A, Moon JJ, Scheetz L, Lahann J, Mauser A, Lowenstein PR, Castro MG.
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development.
Expert Opin Investig Drugs. [2020 May 13]. 2020;1-26. Doi 10.1080/13543784.2020.1768528. _




Li J, Zhao J, Tan T, Liu M, Zeng Z, Zeng Y, Zhang L, Fu C, Chen D, Xie T.
Nanoparticle Drug Delivery System for Glioma and Its Efficacy Improvement Strategies: A Comprehensive Review.
Int J Nanomedicine. 2020 Apr 17. 2020;15:2563-2582. Doi 10.2147/IJN.S243223. _




Mi Y, Guo N, Luan J, Cheng J, Hu Z, Jiang P, Jin W, Gao X.
The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment.
Front Immunol. 2020 Apr 24. 2020;11:737. Doi 10.3389/fimmu.2020.00737. _




Suarez-Meade P, Marenco-Hillembrand L, Prevatt C, Murguia-Fuentes R, Mohamed A, Alsaeed T, Lehrer EJ, Brigham T, Ruiz-Garcia H, Sabsevitz D, Middlebrooks EH, Bechtle PS, Quinones-Hinojosa A, Chaichana KL.
Awake vs. asleep motor mapping for glioma resection: a systematic review and meta-analysis.
Acta Neurochir (Wien). [2020 May 9]. 2020;10.1007/s00701-020-04357-y. Doi 10.1007/s00701-020-04357-y. _




Suvà ML, Tirosh I.
The Glioma Stem Cell Model in the Era of Single-Cell Genomics.
Cancer Cell. 2020 May 11. 2020;37(5):630-636. Doi 10.1016/j.ccell.2020.04.001. _




Tuleasca C, Knisely J, Leroy HA, Hottinger AF, Peciu-Florianu I, Levivier M, Reyns N.
Glioma patient-reported outcome assessment in clinical care.
Lancet Oncol. 2020 May 1. 2020;21(5):e230. Doi 10.1016/S1470-2045(20)30141-8. _
Referring to: Armstrong TS, et al.,Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. Lancet Oncol. 2020 Feb 1. 2020;21(2):e97-e103. Doi 10.1016/S1470-2045(19)30796-X. _



HIGH-GRADE GLIOMAS



Ali AS, Chen VE, Zurlo C, Taylor JM, Fernandez C, Shi W.
Target treatment with stereotactic radiation for recurrent gliomas.
Chin Clin Oncol. [2020 Apr 28]. 2020;cco.2020.03.05. Doi 10.21037/cco.2020.03.05. _




Broekx S, Weyns F, De Vleeschouwer S.
5-Aminolevulinic acid for recurrent malignant gliomas: A systematic review.
Clin Neurol Neurosurg. [2020 May 16]. 2020;195:105913. Doi 10.1016/j.clineuro.2020.105913. _




Khan L, Soliman H, Sahgal A, Perry J, Xu W, Tsao MN.
External beam radiation dose escalation for high grade glioma.
Cochrane Database Syst Rev. 2020 May 21. 2020;5:CD011475. Doi 10.1002/14651858.CD011475.pub3. _




Luo C, Xu S, Dai G, Xiao Z, Chen L, Liu Z.
Tumor treating fields for high-grade gliomas.
Biomed Pharmacother. [2020 May 11]. 2020;127:110193. Doi 10.1016/j.biopha.2020.110193._



LOW-GRADE GLIOMAS



Collins KL, Pollack IF.
Pediatric Low-Grade Gliomas.
Cancers (Basel). 2020 May 4. 2020;12(5):E1152. Doi 10.3390/cancers12051152. _




de Blank P, Fouladi M, Huse JT.
Molecular markers and targeted therapy in pediatric low-grade glioma.
J Neurooncol. [2020 May 12]. 2020;10.1007/s11060-020-03529-1. Doi 10.1007/s11060-020-03529-1. _




Dimou J, Kelly J.
The biological and clinical basis for early referral of low grade glioma patients to a surgical neuro-oncologist.
J Clin Neurosci. [2020 May 4]. 2020;S0967-5868(19)31963-0. Doi 10.1016/j.jocn.2020.04.119. _




Sidaway P.
Low-grade glioma subtypes revealed.
Nat Rev Clin Oncol. [2020 April 30]. 2020;17(6):335. Doi 10.1038/s41571-020-0380-4. _
Referring to: Ryall S, et al., Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell. 2020 Apr 13. 2020;37(4):569‐583.e5. Doi 10.1016/j.ccell.2020.03.011. _




Young JS, Gogos AJ, Morshed RA, Hervey-Jumper SL, Berger MS.
Molecular characteristics of diffuse lower grade gliomas: what neurosurgeons need to know.
Acta Neurochir (Wien). [2020 May 30]. 2020;10.1007/s00701-020-04426-2. Doi 10.1007/s00701-020-04426-2. _



DIFFUSE ASTROCYTIC AND OLIGODENDROGLIAL TUMORS



GLIOBLASTOMA



Azzarelli R.
Organoid Models of Glioblastoma to Study Brain Tumor Stem Cells.
Front Cell Dev Biol. 2020 Apr 16. 2020;8:220. Doi 10.3389/fcell.2020.00220. _




Ciccocioppo F, Lanuti P, Marchisio M, Miscia S.
Extracellular Vesicles Involvement in the Modulation of the Glioblastoma Environment.
J Oncol. 2020 Jan 28. 2020;2020:3961735. Doi 10.1155/2020/3961735. _




Delgado-Martín B, Medina MÁ.
Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment.
Adv Sci (Weinh). [2020 Mar 12]. 2020;7(9):1902971. Doi: 10.1002/advs.201902971. _




Ferrer AI, Trinidad JR, Sandiford O, Etchegaray JP, Rameshwar P.
Epigenetic dynamics in cancer stem cell dormancy.
Cancer Metastasis Rev. [2020 May 12]. 2020;10.1007/s10555-020-09882-x. Doi 10.1007/s10555-020-09882-x. _




Hassn Mesrati M, Behrooz AB, Y Abuhamad A, Syahir A.
Understanding Glioblastoma Biomarkers: Knocking a Mountain with a Hammer.
Cells. 2020 May 16. 2020;9(5):E1236. Doi 10.3390/cells9051236. _




Kirstein A, Schmid TE, Combs SE.
The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme.
Cancers (Basel). 2020 Apr 28. 2020;12(5):E1099. Doi 10.3390/cancers12051099. _




Lee A, Arasaratnam M, Chan DLH, Khasraw M, Howell VM, Wheeler H.
Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Cochrane Database Syst Rev. 2020 May 12. 2020;5:CD013238. Doi 10.1002/14651858.CD013238.pub2. _




Li R, Li C, Cai Z, Li L, Wei L, Qian Z, Zhou D.
Comparative efficacy of antiangiogenic treatment for newly diagnosed glioblastoma: A protocol for systematic review and network meta-analysis.
Medicine (Baltimore). 2020 May;99(19):e20011. Doi 10.1097/MD.0000000000020011. _




Liu EK, Sulman EP, Wen PY, Kurz SC.
Novel Therapies for Glioblastoma.
Curr Neurol Neurosci Rep. 2020 May 22. 2020;20(7):19. Doi 10.1007/s11910-020-01042-6. _




Mazurek M, Grochowski C, Litak J, Osuchowska I, Maciejewski R, Kamieniak P.
Recent Trends of microRNA Significance in Pediatric Population Glioblastoma and Current Knowledge of Micro RNA Function in Glioblastoma Multiforme.
Int J Mol Sci. 2020 Apr 27. 2020;21(9):3046. Doi 10.3390/ijms21093046. _




Miller AM, DeAngelis LM.
Reevaluation of the Frequent Use of PD-1 Checkpoint Inhibitors for Treatment of Glioblastoma.
JAMA. [2020 May 26]. 2020;10.1001/jama.2020.5934. Doi 10.1001/jama.2020.5934. _
Referring to: Reardon DA, et al.,Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. [2020 May 21]. 2020;e201024. Doi 10.1001/jamaoncol.2020.1024. _




Montemurro N, Anania Y, Cagnazzo F, Perrini P.
Survival outcomes in patients with recurrent glioblastoma treated with Laser Interstitial Thermal Therapy (LITT): A systematic review.
Clin Neurol Neurosurg. [2020 May 21]. 2020;195:105942. Doi 10.1016/j.clineuro.2020.105942. _




Muir M, Gopakumar S, Traylor J, Lee S, Rao G.
Glioblastoma multiforme: novel therapeutic targets.
Expert Opin Ther Targets. [2020 May 12]. 2020;1-10. Doi 10.1080/14728222.2020.1762568. _




Muster V, Gary T.
Incidence, Therapy, and Bleeding Risk-Cancer- Associated Thrombosis in Patients with Glioblastoma.
Cancers (Basel). 2020 May 26. 2020;12(6):E1354. Doi 10.3390/cancers12061354. _




Pinto G, Brou C, Zurzolo C.
Tunneling Nanotubes: The Fuel of Tumor Progression?
Trends Cancer. [2020 May 26]. 2020;S2405-8033(20)30155-2. Doi 10.1016/j.trecan.2020.04.012. _




Rahman M, Sawyer WG, Lindhorst S, Deleyrolle LP, Harrison JK, Karachi A, Dastmalchi F, Flores-Toro J, Mitchell DA, Lim M, Gilbert MR, Reardon DA.
Adult Immuno-Oncology: Using Past Failures to Inform the Future.
Neuro Oncol. [2020 May 11]. 2020;noaa116. Doi 10.1093/neuonc/noaa116. _




Schulte JD, Aghi MK, Taylor JW.
Anti-angiogenic therapies in the management of glioblastoma.
Chin Clin Oncol. [2020 Apr 21]. 2020;cco.2020.03.06. Doi 10.21037/cco.2020.03.06. _




Shu C, Li Q.
Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
Crit Rev Oncol Hematol. [2020 Apr 24]. 2020;151:102965. Doi 10.1016/j.critrevonc.2020.102965. _




Simon T, Jackson E, Giamas G.
Breaking through the glioblastoma micro-environment via extracellular vesicles.
Oncogene. [2020 May 4]. 2020;39(23):4477-4490. Doi 10.1038/s41388-020-1308-2. _




Silvia N, Dai G.
Cerebral organoids as a model for glioblastoma multiforme.
Curr Opin Biomed Eng. [2020 Mar 25]. 2020;13:152-159. Doi 10.1016/j.cobme.2020.03.004. _




Verma V, Robinson CG, Rusthoven CG.
Hippocampal-Sparing Radiotherapy for Patients With Glioblastoma and Grade II-III Gliomas.
JAMA Oncol. [2020 May 14]. 2020;10.1001/jamaoncol.2020.0164. Doi 10.1001/jamaoncol.2020.0164. _




Weller M, Le Rhun E.
How did lomustine become standard of care in recurrent glioblastoma?
Cancer Treat Rev. [2020 May 4]. 2020;87:102029. Doi 10.1016/j.ctrv.2020.102029. _




Yan G, Wang Y, Chen J, Zheng W, Liu C, Chen S, Wang L, Luo J, Li Z.
Advances in drug development for targeted therapies for glioblastoma.
Med Res Rev. [2020 May 23]. 2020;10.1002/med.21676. Doi 10.1002/med.21676. _




Zhang C, Du J, Xu W, Huang H, Gao L.
The Value of Tumor Treating Fields in Glioblastoma.
J Korean Neurosurg Soc. [2020 May 8]. 2020;10.3340/jkns.2019.0224. Doi 10.3340/jkns.2019.0224. _



DIFFUSE MIDLINE GLIOMA



Kraus TFJ, Machegger L, Pöppe J, Zellinger B, Dovjak E, Schlicker HU, Schwartz C, Ladisich B, Spendel M, Kral M, Reinhardt A, Winkler PA, Sotlar K.
Diffuse midline glioma of the cervical spinal cord with H3 K27M genotype phenotypically mimicking anaplastic ganglioglioma: a case report and review of the literature.
Brain Tumor Pathol. [2020 May 25]. 2020;10.1007/s10014-020-00365-z. Doi: 10.1007/s10014-020-00365-z. _




Lu VM, Power EA, Zhang L, Daniels DJ.
Overcoming the blood brain barrier to target diffuse intrinsic pontine glioma: What's new?
World Neurosurg. [2020 May 7]. 2020:S1878-8750(20)30968-2. Doi 10.1016/j.wneu.2020.05.008. _



EMBRYONAL TUMORS



MEDULLOBLASTOMA



Cuccia F, Mortellaro G, Ognibene L, Craparo G, Lo Casto A, Ferrera G.
Salvage Re-irradiation Options in Adult Medulloblastoma: A Case Report and Review of the Literature.
In Vivo. 2020 May-Jun;34(3):1283-1288. Doi 10.21873/invivo.11903. _




Kabir TF, Kunos CA, Villano JL, Chauhan A.
Immunotherapy for Medulloblastoma: Current Perspectives.
Immunotargets Ther. 2020 Apr 20. 2020;9:57-77. Doi 10.2147/ITT.S198162. _




Nantavithya C, Paulino AC, Liao K, McGovern SL, Grosshans DR, McAleer MF, Woodhouse KD, Khatua S, Chintagumpala MM, Majd NK, Yeboa DN.
Development of second primary tumors and outcomes in medulloblastoma by treatment modality: A Surveillance, Epidemiology, and End Results analysis.
Pediatr Blood Cancer. [2020 May 26]. 2020;e28373. Doi 10.1002/pbc.28373. _




Ritchey AK, et al., PDQ Pediatric Treatment Editorial Board.
Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®): Patient Version.
PDQ Cancer Inf Summ. 2020 May 7. Natl Cancer Inst. NBK65964. _



LYMPHOMAS


Wang H, Zhou Y, Li L, Hou W, Ma X, Tian R.
Current status and quality of radiomics studies in lymphoma: a systematic review.
Eur Radiol. [2020 May 29]. 2020;10.1007/s00330-020-06927-1. Doi 10.1007/s00330-020-06927-1. _



FAMILIAL TUMOR SYNDROMES


Brosseau JP, Liao CP, Le LQ.
Translating current basic research into future therapies for neurofibromatosis type 1.
Br J Cancer. [2020 May 22]. 2020;10.1038/s41416-020-0903-x. Doi 10.1038/s41416-020-0903-x. _



bottom